Litcius/Paper detail

Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

Christoph Rummelt, Sivahari Prasad Gorantla, Manja Meggendorfer, Anne Charlet, Cornelia Endres, Konstanze Döhner, Florian H. Heidel, Thomas Fischer, Torsten Haferlach, Justus Duyster, Nikolas von Bubnoff

2020Leukemia46 citationsDOI

Topics & Concepts

Fms-Like Tyrosine Kinase 3Cancer researchSorafenibSTAT5BiologyMutationMidostaurinIn vivoTyrosine kinaseGene knockdownCell cultureSignal transductionMyeloid leukemiaGeneticsGeneHepatocellular carcinomaAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo | Litcius